RT Journal Article
SR Electronic
T1 Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.16.22276513
DO 10.1101/2022.06.16.22276513
A1 Meredith A. Mortberg
A1 Sonia M. Vallabh
A1 Eric Vallabh Minikel
YR 2022
UL http://medrxiv.org/content/early/2022/06/21/2022.06.16.22276513.abstract
AB Background Neurodegenerative disease is increasing in prevalence and remains without disease-modifying therapies, and most trials of new drugs fail. Proposed solutions include aiming upstream: targeting molecular root causes of disease and testing therapies earlier, even at pre-symptomatic stages. We sought to understand what disease stages were eligible to enroll in neurodegenerative disease clinical trials in recent years and what molecular targets were tested in these trials.Methods We combined automated analysis and manual curation of trial registrations from ClinicalTrials.gov for Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia / amyotrophic lateral sclerosis, and Huntington’s disease.Findings 3,241 trials from 2000-2020 were curated. Industry-sponsored drug trials, a minority (34%) of trials but a majority (61%) of patient-years, were more likely to complete, to have specified phase, and to have placebo or standard-of-care control arms. The mean number of inclusion and exclusion criteria more than doubled over this period, and eligible score ranges shrank. Trials have shifted towards less severely impaired participants, but only 2.7% of trials were open to pre-symptomatic individuals and these were depleted for industry sponsors (OR = 0.32) and for drug trials (OR = 0.59), instead being enriched for behavioral interventions (OR = 3.1). 16 novel, genetically supported therapeutic hypotheses have been tested in drug trials, with a mean lag of 13 years from genetic association to first trial. Such trials comprised just 18% of patient-years.Interpretation Eligibility criteria for trials have shifted towards earlier, milder disease stages but are still overwhelmingly focused on symptomatic patients, particularly for industry-sponsored drug trials. Drugs targeting disease genes supported by human genetics comprise a small fraction of drug development effort, and their success may be hindered by a focus on symptomatic patients.Competing Interest StatementMAM reports no disclosures. SMV has received speaking fees from Ultragenyx, Illumina, and Biogen, consulting fees from Invitae, and research support in the form of unrestricted charitable contributions from Ionis, Gate, and Charles River. EVM has received consulting fees from Deerfield and research support in the form of unrestricted charitable contributions from Ionis, Gate, and Charles River.Funding StatementThis work was supported by the National Institutes of Health (R21 TR003040 and R01 NS125255). The funder had no role in study design, analysis, interpretation, or decision to publish. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and source code used in this study will be made publicly available at http://github.com/ericminikel/nd_trials and are sufficient to reproduce the figures and statistics herein. https://github.com/ericminikel/nd_trials